Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

VERTEX PH Form 4 May 01, 200	HARMACEUTIC	CALS ING	C/MA								
FORN Check th	RITIES A shington,		OMB AF OMB Number: Expires:	APPROVAL 3235-0287 January 31,							
if no long subject to Section 1 Form 4 o Form 5 obligation may cont <i>See</i> Instru 1(b).	6. Filed pur inue.	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section									
(Print or Type I	Responses)										
BOGER KENNETH S Symbol VERTE				Name and X PHAR	MACEU		-	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3. Date of (Month/E) C/O VERTEX 04/30/2 PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET					ansaction			Director10% Owner XOfficer (give titleOther (specify below) below) SVP & General Counsel			
				nth/Day/Year)				6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRID	GE, MA 02139							Form filed by M Person	lore than One Re	porting	
(City)	(State)	(Zip)	Tabl	e I - Non-D	erivative S	Securi	ities Acqu	uired, Disposed of	, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transactio Code (Instr. 8) Code V	4. Securiti n(A) or Dis (Instr. 3, 4)	sposed	l of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock	04/30/2007			М	12,000	А	\$ 10.41	128,361	D		
Common Stock	04/30/2007			S <u>(1)</u>	12,000	D	\$ 31.35	116,361	D		
Common Stock								1,000	Ι	Held by minor children	
Common								4,271	I	401(k)	

Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

Stock

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Options	\$ 10.41	04/30/2007		М	12,000	05/03/2005 <u>(2)</u>	02/02/2015	Common Stock	12,000

Reporting Owners

Reporting Owner Name / Address		Relationships					
FB				Officer	Other		
BOGER KENNETH S C/O VERTEX PHARMACEUTICALS II 130 WAVERLY STREET CAMBRIDGE, MA 02139	NCORPORATED			SVP & General Counsel			
Signatures							
Valerie L. Andrews, Attorney-In-fact	05/01/2007						

**Signature of Reporting Person

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to Mr. Boger's company approved trading plan established under rule 10b5-1.

Date

(2) Right to buy under 1996 Stock and Option Plan, vesting quarterly over 4 years from 2/3/2005.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.